

### SECTION-1: Identification of the substance / mixture and the company / undertaking

<b>Catalogue Number</b>	CS-L-00152
<b>Product Name</b>	Enfuvirtide
<b>CAS No.</b>	159519-65-0
<b>Category</b>	API
<b>Synonyms</b>	Not available
<b>Brand</b>	Clearsynth Labs Ltd.
<b>Identified uses</b>	Laboratory Chemicals
<b>Uses advised against</b>	Not available
<b>Company</b>	Clearsynth Labs Ltd. Mumbai, India
<b>Emergency Phone #</b>	+91-22-245045900
<b>REACH No.</b>	Not available

### SECTION 2: Hazards identification

**Disclaimer:** This is sample MSDS. Please email [sales@clearsynth.com](mailto:sales@clearsynth.com) for more details.

#### 2.1 Classification of the substance or mixture-Regulation (EC) No 1272/2008:

Not available

#### 2.2 Label Elements

**Signal Word:** Warning

Not available

#### Hazard Statement(s)

Code	Statement
H317	May cause an allergic skin reaction.

#### Precautionary Statement(s)

Code	Statement
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P272	Not available
P280	Wear protective gloves/protective clothing/eye protection/face protection.

P302+P352	IF ON SKIN: Wash with plenty of water and soap.
P321	Specific treatment (see ... on this label).
P333+P317	Not available
P362+P364	Take off contaminated clothing and wash it before reuse.
P501	Dispose of contents/container in accordance with local/regional/national/international regulation

### SECTION 3: Composition / information on ingredients

#### 3.1 Substance

Component : Enfuvirtide

CAS Number : 159519-65-0

Molecular Formula : Not available

Molecular Weight : Not available

Parent Chemical : Not available

Synonyms : Not available

Concentration : Not available

### SECTION 4: First aid measures

#### SECTION 4: First-aid measures

##### 4.1 Description of first aid measures

- General advice: Remove from exposure. Show this SDS to the physician in attendance.
- Inhalation: Move person to fresh air. If breathing is difficult, seek medical attention.
- Skin contact: Wash with plenty of soap and water. Remove contaminated clothing and wash before reuse. Get medical attention if irritation persists.
- Eye contact: Rinse cautiously with water for several minutes. Remove contact lenses if present and easy to do. Continue rinsing. Seek medical attention if irritation persists.
- Ingestion: Rinse mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention.

##### 4.2 Most important symptoms and effects, both acute and delayed

- Not available.

##### 4.3 Indication of any immediate medical attention and special treatment needed

- Treat symptomatically. No data available.

### SECTION 5: Firefighting measures

#### SECTION 5: Fire-fighting measures

##### 5.1 Extinguishing media

- Suitable extinguishing media: Water spray, alcohol-resistant foam, dry chemical, carbon dioxide.
- Unsuitable extinguishing media: Not available.

##### 5.2 Special hazards arising from the substance or mixture

- Specific hazards: No data available.
- Hazardous combustion products: Not available.

### 5.3 Advice for firefighters

- Wear self-contained breathing apparatus (SCBA) and full protective gear.
- Use water spray to cool unopened containers.

## SECTION 6: Accidental release measures

### SECTION 6: Accidental release measures

#### 6.1 Personal precautions, protective equipment and emergency procedures

- Avoid breathing dust/aerosols.
- Avoid contact with skin and eyes.
- Use appropriate personal protective equipment (see Section 8).

#### 6.2 Environmental precautions

- Prevent further leakage or spillage if safe to do so.
- Avoid release to the environment. No data available on environmental precautions specific to this material.

#### 6.3 Methods and material for containment and cleaning up

- Contain spill.
- Collect spilled material using methods that minimize dust generation (e.g., damp wipe or HEPA-filtered vacuum).
- Place in a suitable, closed container for disposal.

#### 6.4 Reference to other sections

- See Section 8 for exposure controls/personal protection and Section 13 for disposal considerations.

## SECTION-7: Handling and storage

### SECTION 7: Handling and storage

#### 7.1 Precautions for safe handling

- Handle in accordance with good industrial hygiene and safety practice.
- Avoid formation of dust.
- Avoid breathing dust/aerosols.
- Avoid contact with skin, eyes, and clothing.
- Wash hands thoroughly after handling.

#### 7.2 Conditions for safe storage, including any incompatibilities

- Store in a tightly closed container.
- Store in a cool, dry, well-ventilated place.
- Protect from moisture.
- Incompatible materials: Not available.

#### 7.3 Specific end use(s)

- API. No additional information available.

## SECTION 8: Exposure controls / personal protection

### SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

- Occupational exposure limits: Not available.
- Biological limit values: Not available.

### 8.2 Exposure controls

- Engineering controls: Use local exhaust ventilation or other engineering controls to minimize airborne exposure.
- Personal protective equipment (PPE):
  - Eye/face protection: Safety glasses with side shields or chemical goggles.
  - Skin protection: Protective gloves. Protective clothing as appropriate.
  - Respiratory protection: If ventilation is inadequate or dust is generated, use a NIOSH/EN-approved particulate respirator as appropriate.
- Hygiene measures: Do not eat, drink, or smoke when using this product. Wash hands after handling.

## SECTION 9: Physical and chemical properties

### 9.1 Information on basic physical and chemical properties

Test	Result
Appearance	No data available
IR spectrum	No data available
pH	No data available
Solubility	No data available

Property	Value
a) Physical State	No data available
b) Color	No data available
c) Odor	No data available
d) pH	No data available
e) Vapour Pressure	No data available
f) Viscosity	No data available
g) Initial Boiling Point and boiling range	No data available
h) Melting Point / Freezing Point	No data available
i) Auto Ignition Temperature	No data available
j) Flash Point	No data available
k) Explosion Limit, Lower	No data available

Property	Value
l) Explosion Limit, Upper	No data available
m) Decomposition Temperature	No data available
n) Loss on Drying	No data available
o) Relative Density	No data available
p) Solubility (in DMSO)	No data available
q) Oxidizing Properties	No data available

### SECTION 10: Stability and reactivity

#### SECTION 10: Stability and reactivity

##### 10.1 Reactivity

- No data available.

##### 10.2 Chemical stability

- Stable under recommended storage conditions. No data available.

##### 10.3 Possibility of hazardous reactions

- No data available.

##### 10.4 Conditions to avoid

- Avoid dust formation. Avoid moisture. No data available.

##### 10.5 Incompatible materials

- Not available.

##### 10.6 Hazardous decomposition products

- Not available.

### SECTION 11: Toxicological information

#### 11.1 Information on toxicological effects

- Acute toxicity: /LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Reproduction studies have been performed in rats and rabbits at doses up to 27 times and 3.2 times the adult human dose on a sq m basis. The animal studies revealed no evidence of harm to the fetus from enfuvirtide. /LABORATORY ANIMALS:

Developmental or Reproductive Toxicity/ Enfuvirtide produced no adverse effects on fertility in male or female rats at doses of up to 30 mg/kg/day administered by subcutaneous injection.

- Skin corrosion/irritation: No data available.

- Serious eye damage/eye irritation: No data available.

- Respiratory or skin sensitization: No data available.

- Germ cell mutagenicity: /GENOTOXICITY/ Enfuvirtide was neither mutagenic nor clastogenic in a series of in vivo and invitro assays including the Ames bacterial reverse mutation assay, a mammalian cell forward gene assay in AS52 Chinese Hamster ovary cells or an in vivo mouse micronucleus assay.

- Carcinogenicity: No data available.

- Reproductive toxicity: /LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Reproduction studies have been performed in rats and rabbits at doses up to 27 times and 3.2 times the adult human dose on a sq m basis. The animal studies revealed no evidence of harm to the fetus from enfuvirtide. /LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Enfuvirtide produced no adverse effects on fertility in male or female rats at doses of up to 30 mg/kg/day administered by subcutaneous injection.
- STOT-single exposure: No data available.
- STOT-repeated exposure: No data available.
- Aspiration hazard: No data available.

Likely routes of exposure

- No data available.

Symptoms related to the physical, chemical and toxicological characteristics

- /SIGNS AND SYMPTOMS/ Hypersensitivity reactions, including rash, fever, nausea and vomiting, chills, rigors, hypotension, and elevated serum liver transaminase concentrations, have been reported in up to 1% of patients receiving enfuvirtide; these hypersensitivity reactions have recurred on rechallenge. Other adverse events reported in patients receiving enfuvirtide that may be immune mediated include primary immune complex reactions, respiratory distress, glomerulonephritis, and Guillain-Barre syndrome. Patients experiencing signs and symptoms suggestive of a systemic hypersensitivity reaction should discontinue enfuvirtide and seek immediate medical evaluation. Enfuvirtide therapy should not be reinitiated in patients who have experienced systemic signs and symptoms consistent with a hypersensitivity reaction while receiving the drug.

## SECTION 12: Ecological information

SECTION 12: Ecological information

12.1 Toxicity

- Not available.

12.2 Persistence and degradability

- Not available.

12.3 Bioaccumulative potential

- Not available.

12.4 Mobility in soil

- Not available.

12.5 Results of PBT and vPvB assessment

- Not available.

12.6 Endocrine disrupting properties

- Not available.

12.7 Other adverse effects

- Not available.

## SECTION 13: Disposal considerations

SECTION 13: Disposal considerations

13.1 Waste treatment methods

- Dispose of contents/container in accordance with local/regional/national/international regulations.
- Do not discharge to drains or the environment.
- Recommended disposal method: Not available.
- Contaminated packaging: Dispose of as unused product.

### SECTION 14: Transport information

#### SECTION 14: Transport information

- UN number: Not available.
- UN proper shipping name: Not available.
- Transport hazard class(es): Not available.
- Packing group: Not available.
- Environmental hazards: Not available.
- Special precautions for user: Not available.
- Transport in bulk according to IMO instruments: Not available.

### SECTION 15: Regulatory information

#### SECTION 15: Regulatory information

##### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

- Not available.

##### 15.2 Chemical safety assessment

- Not available.

### SECTION 16: Other information

#### SECTION 16: Other information

- Product name: Enfuvirtide
- Catalog No.: CS-L-00152
- CAS No.: 159519-65-0
- Supplier: Clearsynth Labs Ltd., Mumbai, India
- Emergency phone: +91-22-245045900

#### Disclaimer

- The information provided in this SDS is based on data believed to be reliable; however, no warranty is expressed or implied regarding the accuracy or completeness of this information. The user is responsible for determining suitability for a particular purpose and for complying with applicable laws and regulations.

### DISCLAIMER

This MSDS is system-generated. Please verify and confirm all data, statements, and values with the Support Team before use or distribution.